Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
CDK4/6 and Cyclin D1 are significantly expressed in approximately 80% of esophageal and
gastroesophageal junction tumors suggesting that CDK4/6 inhibition may be a successful
strategy in these chemotherapy and immunotherapy resistant diseases.